

***In vivo* expression technology and 5' end mapping of the *Borrelia burgdorferi* transcriptome identify novel RNAs expressed during mammalian infection**

Philip P. Adams¹, Carlos Flores Avile¹, Niko Popitsch², Ivana Bilusic³, Renée Schroeder³, Meghan Lybecker⁴ and Mollie W. Jewett^{1,*}

¹Division of Immunity and Pathogenesis, Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL 32827, USA, ²Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK, ³Department of Biochemistry and Cell Biology, Max F. Perutz Laboratories, University of Vienna, Vienna 1030, Austria and ⁴Department of Biology, University of Colorado Colorado Springs, Colorado Springs, CO 80918, USA

Received August 17, 2016; Revised October 18, 2016; Editorial Decision November 14, 2016; Accepted November 15, 2016

ABSTRACT

***Borrelia burgdorferi*, the bacterial pathogen responsible for Lyme disease, modulates its gene expression profile in response to the environments encountered throughout its tick-mammal infectious cycle. To begin to characterize the *B. burgdorferi* transcriptome during murine infection, we previously employed an *in vivo* expression technology-based approach (BbIVET). This identified 233 putative promoters, many of which mapped to un-annotated regions of the complex, segmented genome. Herein, we globally identify the 5' end transcriptome of *B. burgdorferi* grown in culture as a means to validate non-ORF associated promoters discovered through BbIVET. We demonstrate that 119 BbIVET promoters are associated with transcription start sites (TSSs) and validate novel RNA transcripts using Northern blots and luciferase promoter fusions. Strikingly, 49% of BbIVET promoters were not found to associate with TSSs. This finding suggests that these sequences may be primarily active in the mammalian host. Furthermore, characterization of the 6042 *B. burgdorferi* TSSs reveals a variety of RNAs including numerous antisense and intragenic transcripts, leaderless RNAs, long untranslated regions and a unique nucleotide frequency for initiating intragenic transcription. Collectively, this is the first comprehensive map of TSSs in *B. burgdorferi* and characterization of previously un-annotated RNA transcripts expressed by the spirochete during murine infection.**

INTRODUCTION

Borrelia burgdorferi or *Borrelia burgdorferi* (1) is the spirochetal agent of Lyme disease, the foremost vector-borne bacterial disease in the world (2). *B. burgdorferi* is naturally maintained in an enzootic cycle between an arthropod vector, *Ixodes sp.* ticks and diverse small vertebrate reservoir hosts, such as the white-footed mouse *Peromyscus leucopus* (3). Humans may become infected with *B. burgdorferi* through the bite of an infected tick, resulting in Lyme disease (4). The survival and pathogenesis of *B. burgdorferi* requires that the bacterium appropriately modifies its transcription profile in response to the distinct tick vector and mammalian host environments encountered throughout its infectious cycle (5–7). The paradigm example of this is the down-regulation of *ospA*, encoding outer surface protein A and up-regulation of *ospC*, encoding outer surface protein C, during *B. burgdorferi* transmission from the feeding tick to the mammalian host (8–12). Elucidation of the transcriptional activity of a pathogen during infection is critical for understanding the molecular mechanisms used by the pathogen to cause disease. Yet, despite the well characterized transcriptomes of other pathogens (13–17), *B. burgdorferi*'s paucibacillary nature (18) has led to technical challenges toward global elucidation of the spirochete's transcription profile during mammalian infection.

Global transcriptome approaches performed using *B. burgdorferi* cultivated in modified growth conditions, used to simulate tick or mammalian environments, have allowed interrogation of the spirochete's gene expression profile in response to diverse stimuli. Temperature and pH shift of bacterial cultures in complex medium (19,20), co-incubation of spirochetes with host cells (21) and growth of *B. burgdorferi* in blood (22), or in dialysis membrane chambers in the peritoneal cavities of rats (7,23,24), have resulted

*To whom correspondence should be addressed. Tel: +407 266 7028; Fax: +407 266 7002; Email: Mollie.Jewett@ucf.edu

in the discovery of a number of *B. burgdorferi* genes that are expressed under mammalian infection-like conditions and contribute to pathogenesis (5). However, these modeled conditions are unable to fully recapitulate the complex tissue environments that *B. burgdorferi* encounters during an active infection. Recently, an amplification-microarray approach was used to define the transcription profile of annotated open reading frames and pseudogenes in fed larval ticks, fed nymphal ticks and mammalian host adapted *B. burgdorferi* cultivated in dialysis membrane chambers (7). This analysis provided stage-specific mRNA expression levels and insights into the transcriptional network that the spirochete uses to sense and respond to the environmental cues it receives as it transitions between the tick vector and mammalian host (7). Microarray analysis of *B. burgdorferi* gene expression in a non-human primate model of neuroborreliosis revealed genes that are specifically induced in the central nervous system during infection (25). Targeted analyses of specific gene subsets have identified a number of *B. burgdorferi* genes that are upregulated during mouse infection (5,18,26). In addition, global mutagenesis approaches have identified a number of genes that contribute to murine infection (27,28). Nonetheless much remains to be discovered about the *B. burgdorferi* transcriptome and how it contributes to the spirochete's pathogenesis.

To overcome the challenges of identifying *B. burgdorferi* genes expressed during murine infection, our lab developed an *in vivo* expression technology (IVET)-based approach for *B. burgdorferi* (BbIVET) (29). IVET is a powerful and versatile promoter identification method and has been used with pathogenic bacteria and fungi in a wide variety of host environments, and led to the discovery of a number of previously uncharacterized virulence genes (30–34). This approach does not rely on the recovery of bacterial RNA from mouse tissues for transcriptional analysis and thus is not hindered by low bacterial numbers during infection. BbIVET was the first genetic screen of this type to identify *B. burgdorferi* putative promoter sequences that are transcriptionally active during a murine infection. Moreover, the experimental design of the BbIVET screen was such that the recovered infection-active promoters could be active both in culture and during infection or specifically active during infection alone. We previously reported the BbIVET-identified sequences that mapped upstream of annotated open reading frames (ORFs) (29). Unexpectedly, many sequences discovered through BbIVET were internal, antisense or intergenic to ORFs. This suggested the presence of novel transcripts in these genomic regions; however, due to the lack of *B. burgdorferi* RNA-seq studies that report transcripts other than annotated mRNAs, the significance of these findings were unknown.

Since their development, 5' end RNA-seq protocols have been used to globally define transcription start sites (TSSs) and processed RNA 5' ends across bacterial genomes. The initial use of this technique revealed the complexity of the *Helicobacter pylori* transcriptome through the discovery of global antisense transcription, numerous small regulatory RNAs (sRNAs) and previously unrecognized intragenic TSSs (35). Furthermore, 5' end RNA-seq applications in other organisms have identified high instances of leader-

less transcripts (36), novel regulatory RNA networks (37–39), strain-specific sRNAs (40) and a high prevalence of unannotated small proteins (41), as well as provided valuable resources for future genetic applications in model organisms (42).

As a means to gain insight into the significance of the unannotated sequences identified through BbIVET, as well as work to elucidate the BbIVET promoters that are principally active during infection alone, we have applied 5' end RNA deep sequencing (5'RNA-seq) to *B. burgdorferi* grown in culture and overlapped this TSS map with the BbIVET-identified sequences. We provide substantial genome-wide data on the transcriptional start sites for *B. burgdorferi* and validate the expression of a subset of these both in culture and during an active murine infection. In total, this work contributes significant understanding to the complex transcriptome of *B. burgdorferi* and identifies novel *B. burgdorferi* sequences expressed during mammalian infection.

MATERIALS AND METHODS

Bacterial clones and growth conditions

Borrelia burgdorferi clones used in this study were derived from strain B31. Wild-type clone B31 A3 (43), which lacks cp9, was used for the cDNA library preparations. All *B. burgdorferi* genetic manipulations used infectious low-passage clone A3-68ΔBBE02, which lacks cp9, lp56 and gene *bbe02* on lp25 (44). All shuttle vectors were created in DH5α *Escherichia coli*, grown in LB broth or on LB agar plates containing 300 μg/ml spectinomycin when appropriate, and transformed into *B. burgdorferi* as previously described (45). Spirochetes were cultivated in liquid Barbour–Stoenner–Kelly (BSK) II medium supplemented with gelatin and 6% rabbit serum (46) and plated in solid BSK medium as previously described (47). *B. burgdorferi* cultures were grown at 35°C supplemented with 2.5% CO₂ in the presence of 50 μg/ml streptomycin and/or 200 μg/ml kanamycin when applicable.

RNA Isolation

In general, 45 ml of log phase ($3\text{--}7 \times 10^7$ cells/ml) *B. burgdorferi* B31 A3 in BSK II medium, as determined using a Petroff–Hausser counting chamber under dark field microscopy, was pelleted at 3210 ×g for 15 min, supernatant decanted and snap frozen in liquid N₂. Total RNA was extracted using a hot phenol protocol described previously (48). 50 μg total RNA was incubated with 10 U DNase I (Roche) and 80 U rRNasin (Promega) at 37°C for 15 min. The RNA samples were purified as described (48). RNA concentrations were measured and DNA removal and RNA integrity was verified by gel electrophoresis. For RNA preps used in deep-sequencing, RNA integrity number was determined using the Agilent 2100 Bioanalyzer. Samples with RNA integrity numbers over 9.0 were selected for RNA-seq library preparations.

cDNA library preparations

A simplified schematic diagram of the 5'RNA-seq protocol is provided in Supplementary Figure S1. Two biological replicates of *B. burgdorferi* B31 A3 were grown

to a density of 3×10^7 cells/ml in BSK II medium, the presence of all circular and linear plasmids confirmed by PCR with a panel of primers (43), and RNA isolated and DNase treated, as above. Ribo-zeroTM rRNA Removal Kit for Gram-negative bacteria (Epicentre) was used to remove ribosomal RNA, per manufacturer's instructions. Elimination of rRNA was confirmed using an Agilent 2100 Bioanalyzer. A total of 1.5 μ g samples of RNA from each of the two *B. burgdorferi* cultures were incubated at 37°C for 1 h with or without 45 U tobacco acid pyrophosphatase (TAP) (Epicentre), 1X TAP buffer and 40 U rRNasin (Promega). Samples were then loaded into Heavy Phase Lock Gel tubes (5 PRIME) with an equal volume of phenol stabilized:chloroform:isoamyl alcohol (25:24:1) (PCI), ethanol precipitated and reconstituted in 5 μ l DEPC-H₂O. A total of 30 μ M of 5' RNA adapter (5'-GUUCAGUUCUACAGUCCGACGAUC-3'), based on the Illumina adapter sequence, (Oligonucleotide sequences © 2007–2009 Illumina, Inc., all rights reserved) was ligated to the 5' ends of the TAP+ and TAP- treated RNA samples using 20 U RNA Ligase 1 (NEB), 1X RNA Ligase 1 Buffer, 10% DMSO, 1 mM ATP (NEB) and 40 U rRNasin (Promega) in 20 μ l DEPC-H₂O and incubated at 20°C for 6 h. Reactions were then loaded into Heavy Phase Lock Gel tubes (5 PRIME) with equal volume PCI, ethanol precipitated and reconstituted in DEPC-H₂O. Fragmentation of the 5' ligated RNA samples was conducted using RNA fragmentation reagents (Ambion) following manufacturer's instructions with a fragmentation time of 4 min at 70°C. Reactions were ethanol precipitated, reconstituted in DEPC-H₂O and analyzed with an Agilent 2100 Bioanalyzer. RNA libraries were then 3' end dephosphorylated using 10 U T4 Polynucleotide Kinase (PNK) (NEB), minus ATP, with 1X PNK buffer and 20 U rRNasin (Promega) at 37°C for 3 h. A subsequent PCI and ethanol precipitation was performed to purify the libraries, which were then size selected on an 8% polyacrylamide 8 M urea gel. RNA gel segments from ~150–300 nts were isolated and extracted overnight in RNA gel elution buffer (10 mM Tris pH 7.5, 0.1% SDS, 2 mM EDTA, 0.3 M NaOAc) at 4°C with agitation. Gel slurries were loaded onto 0.2 μ m aqua Nanosep[®] MF columns (PALL), centrifuged at 14 000 \times g for 2 min and the eluates were ethanol precipitated. The 3' RNA adapter, based on the Illumina multiplexing sequence and blocked on the 3' end with an inverted dT (5'-(p)AGAUCGGAAGAGCACACGUCU(idT)-3'), was 5' phosphorylated using T4 PNK (NEB) per manufacturer's instructions, and purified using illustra MicroSpin G-25 columns (GE). A total of 52 μ M of phosphorylated 3' RNA adapter was next ligated to the libraries using 25 U RNA Ligase 1 (NEB), 1X RNA Ligase 1 Buffer, 10% DMSO, 1 mM ATP (NEB) and 40 U rRNasin (Promega) in 25 μ l DEPC-H₂O and incubated at 20°C for 6 h. To remove unincorporated adapter, size selection (~200–300 nts) on an 8% polyacrylamide 8 M urea gel was performed and RNA extracted from gel, as described above. Adapter conjugated RNA library preps were converted to cDNA with SuperScriptII reverse transcriptase (Invitrogen) and random nonamers, per manufacturer's instructions. A total of 2 U of RNaseH (Promega) was used to remove the re-

maining RNA from the libraries, and a subsequent 18 cycle PCR with Phusion High-fidelity DNA polymerase (NEB) was used to add appropriate barcodes using ScriptSeq Index Primers (Epicentre) (Supplementary Table S1). Products were analyzed on an Agilent 2100 Bioanalyzer and by KAPA qPCR (KAPABiosystems), and prepared for sequencing with Illumina technology on a HiSeq 1500. Pooled libraries (2 TAP+ and 2 TAP-) were clustered with TruSeq Rapid SR Cluster Kit (Illumina) and sequenced on a rapid run with single-end 50 base-pair reads at the analytical genomics core facility at Sanford Burnham Prebys Medical Discovery Institute (Orlando, FL, USA).

Deep-sequencing analyses

A schematic of the 5'RNA-seq analysis is presented in Supplementary Figure S2. Reads were mapped to the *Borrelia (Borrelia) burgdorferi* B31 genome (GenBank Ids: AE000783, AE001583, AE000793, AE001582, AE000785, AE000794, AE000786, AE000784, AE000789, AE000788, AE000787, AE000790, AE001584, AE000791, AE000792, AE001575, AE001576, AE001577, AE001578, AE001579, AE001580 and AE001581) using NextGenMap v0.4.12 (49) with default configuration but ensuring at least 90% sequence identity between the read and the *B. burgdorferi* B31 reference genome.

The *B. burgdorferi* genome harbors a number of regions comprised of highly repetitive sequence. This is particularly true for sequences residing on the cp32 replicons, lp56, lp21 and lp5 (50). The presence of extensive similarity between sequences found on multiple *B. burgdorferi* plasmids suggested that we may encounter challenges in our ability to definitively map a portion of the 50 bp sequence reads from 5'RNA-seq to their locations in the genome. A dot plot comparing the sequences of all *B. burgdorferi* B31 plasmids to each other confirmed regions of high sequence similarity, especially along the cp32s and lp56, as expected (Supplementary Figure S3A). The same analysis, however, revealed sub-sequences with reduced similarity on these plasmids, which provided evidence that a considerable fraction of the *B. burgdorferi* genome, including sequences on the cp32s and lp56, is sufficiently unique to be mapped with good confidence (Supplementary Figure S3B). For the main analysis we removed aligned reads with mapping quality values below 20, therefore, removing reads that cannot be aligned to a unique location in the genome with high probability. We then extracted one-dimensional, genome-wide signals from the mappable alignments by counting reads that have their 5' nucleotide mapped to a particular genomic position. These signals were normalized by library size. The 5' ends were called in coverage segments of the TAP+ and TAP- signals using an in house method. This procedure excluded peaks below a minimum threshold of 30, which corresponds roughly to a minimum of 30 reads covering a genomic position, and required a 5' end to be sequenced in both biological replicates. For each sequenced 5' end, read counts were averaged between biological replicates and the ratio of reads between the TAP+ and TAP- libraries was then calculated. We observed a strong correlation between the 5' end read counts within the TAP+ and TAP- replicates (Supplementary Figure S4). A 5' end was determined

to be a TSS if the nucleotide reads were at least 2-fold higher in the averaged TAP+ compared to the averaged TAP- libraries. This is based on the notion that TAP hydrolyses phosphodiester bonds on RNA 5' ends and that RNA ligase has specificity to only ligate the 5' Illumina adapter to RNA sequences harboring a 5' monophosphate, thereby enriching TSSs to TAP+ libraries. Ideally, 5'RNA-seq would unambiguously distinguish TSSs from processing events, thereby TAP- libraries would solely sequence processing events. However, practicality, 5'RNA-seq takes a snapshot of an actively growing bacterial population. Given that in routine RNA transcript turnover the 5' triphosphate is removed, combined with unintentional phosphate loss during manipulation of RNA in library preparations, it is not surprising that some TSSs are captured in the TAP- library. Hence a 2-fold threshold was established, as has also been applied to other studies utilizing 5'RNA-seq (37,40). The 5' nucleotides in the TAP+ libraries not identified as TSSs were defined as 5' processed ends. The resulting TSSs were then associated with BbIVET and gene annotations present in the Schutzer annotation set (51) (including tRNA annotations from the UCSC database).

For the analysis that included the repetitive part of the genome, NextGenMap was configured to output the top 100 possible alignments that share the maximum alignment score for each read. These alignments were not filtered for mapping quality and therefore also contained a considerable number of multi-mapped reads with mapping quality zero (MQ0) that map to multiple positions in the reference sequence with equal probability. For such ambiguously mapped reads, the BAM file therefore contained multiple alignment entries. We then extracted a 5' end from these alignments as above but this time each read contributed to this signal only with a weight $1/X0$ to the signal where $X0$ is the number of optimal alignments for this read in the data set. In other words, a uniquely mapped read would count as before; whereas, a read that mapped to three different (repetitive) regions would contribute only $1/3$ to the each of them, thereby equally dividing its contribution among all possible (optimal) mapping locations in the genome.

TSS classifications

A TSS was termed primary if it was located within 300 nucleotides upstream the annotated start codon of an ORF on the same DNA strand, and had the highest average TAP+ read count of all such TSSs associated with the same ORF. Secondary TSSs were those that fulfilled the above criteria with respect to location but were not the TSS with the highest average TAP+ read count. The delegation of antisense was assigned if the TSS was located within or just outside, extending 100 nucleotides (nts) upstream or downstream, of an ORF on the complementary DNA strand. An internal classification was assigned if the TSS was located on the same DNA strand at any position between the second nucleotide of the start codon and the last nucleotide of the stop codon of an ORF. A TSS that was not classified into any of the above categories was identified as an orphan. Each TSS was assigned to all of the categories for which it qualified (Figure 1). There were five cases for which a TSS was assigned the designation of primary for one annotated tran-

script and secondary for another, and three cases for which a TSS was secondary, internal and antisense for three different annotated transcripts (Supplementary Table S2). In each of these situations, the unusual pattern of TSS classification resulted from the close proximity of the TSS to a small ORF or tRNA transcript.

Bbive-TSS association

A conserved Pribnow box sequence was identified, on average, at the -6 nucleotide position relative to unique primary TSSs (Figure 1) and we reasoned that a minimum of 20 nts of a *Bbive* sequence may be sufficient to contain a functional promoter, due to the lack of strong conservation in the -35 region. According to this rationale, we established the criteria that if a TSS was located at a position 20 nts or greater downstream of the 5' end of a *Bbive* sequence up to 6 nts beyond the 3' end of the *Bbive* sequence then it was considered a BbIVET associated TSS (*Bbive*-TSS) (Figure 2).

Northern blotting

Ten micrograms of DNase treated (Roche) total RNA was separated using a formaldehyde/MOPS agarose gel, modified from www.lonza.com/research and (52). Briefly, RNA was denatured in 1X MOPS (20 mM MOPS, 5 mM NaOAc, 1 mM EDTA, pH 7.0), 3.7% formaldehyde and 1X RNA loading dye (ThermoScientific) at 70°C for 10 min, and incubated on ice for 3 min prior to loading. Following separation on a 1% agarose, 1X MOPS, 2% formaldehyde gel at 150V at 4°C, RNA was transferred to Hybond XL membranes (Amersham Pharmacia Biotech) via capillary action overnight (52). Membranes were UV crosslinked with a UVC 500 crosslinker (Amersham Pharmacia Biotech) at 150 mJ, probed with 50 nM DNA oligonucleotide probes (Supplementary Table S1) and end-labeled with ATP (γ - 32 P) by T4 polynucleotide kinase (NEB), at 42°C overnight with ULTRAhyb oligo hybridization buffer (Ambion). Blots were washed twice with 2X SSC (3 M NaCl, 300 mM $\text{Na}_3\text{C}_6\text{H}_5\text{O}_7$), 0.5% SDS, exposed to a phosphor screen and imaged with a Typhoon Trio+ (GE).

Luciferase promoter fusion constructs

B. burgdorferi shuttle vectors pJSB161 and pJSB175 carrying a promoterless or *flaBp*-driven *B. burgdorferi* codon optimized *Photinus pyralis* firefly luciferase gene (*luc*), respectively, were generously provided by Dr Jon Blevins (53). Generation of the *Bbive:luc* fusion constructs was carried out as follows. *Bbive* putative promoter regions, (i) the -1 nucleotide, as determined from 5'RNAseq, to the 5' end of the BbIVET sequence or (ii) the entire *Bbive* sequence, were PCR amplified using Phusion High-fidelity DNA polymerase (NEB) from B31 A3 genomic DNA with primer pairs that introduced a BglII site at the 3' and 5' ends (Supplementary Table S1). For *Bbive*-TSSs, which were located less than 100 nts downstream the 5' end of the BbIVET sequence or for the analysis of processed 5' ends, ~100 bp upstream the TSS/processed 5' end were BglII cloned into pJSB161. The PCR generated DNA fragments were digested with BglII and ligated into BglII digested pJSB161.

The *ospAp:luc* and *ospCp:luc* fusion constructs were generated in the same manner, using primer pairs 1693, 1694 and 1845, 1846, respectively (Supplementary Table S1). All plasmid constructs were confirmed by PCR and sequence analysis.

Luciferase assays

B. burgdorferi clones carrying the luciferase fusion constructs were grown to logarithmic phase ($4\text{--}7 \times 10^7$ spirochetes/ml) in BSK II medium and pelleted at $3210 \times g$ for 10 min. Cells were washed twice with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na_2HPO_4 , 1.8 mM KH_2PO_4 , pH 7.4) and resuspended to approximately $2\text{--}3 \times 10^9$ spirochetes/ml. One hundred microliters of each sample was used to measure the OD600 using a BioTek Synergy 4. A total of 92.5 μl of each sample was loaded into a black, solid bottom 96-well plate (Corning) and combined with 7.5 μl 10 mM D-luciferin (Regis) in PBS. The relative luciferase activity was determined by measuring photon emission in each well for 1 s, 10 times using the EnVision 2104 Multilabel Reader (PerkinElmer). Relative luciferase activity for each sample was averaged, subtracted from the PBS control and normalized to the OD600 reading for that clone, providing the relative luciferase units (RLU) for each promoter fusion. Experiments were conducted in biological triplicate and analyzed by two-tailed Student's t-test relative to pJSB161 using Prism Graphpad.

Ethics statement

The University of Central Florida is accredited by the International Association for Assessment and Accreditation of Laboratory Animal Care. Protocols for all animal experiments were prepared according to the guidelines of the National Institutes of Health and were reviewed and approved by the University of Central Florida Institutional Animal Care and Use Committee.

Luciferase assays during murine infection

Prior to infection and imaging, anaesthetized 6- to 8-week-old female C3H/HeN mice (Envigo) were depilated ventrally by shaving and treatment with odorless hair removal creme (SallyHansen). One week prior to inoculation, and throughout the duration of the study, mice were treated with 5 mg/ml streptomycin and 1 mg/ml Equal® sweetener in their water to maintain selection for the luciferase plasmid in the *B. burgdorferi* clones. Groups of three mice were infected with 1×10^5 spirochetes intraperitoneally. To detect luciferase activity, mice were intraperitoneally injected with 150 mg/kg body weight sterile D-luciferin in PBS, 15 min prior to imaging. The IVIS™ 50 Imaging System (Xenogen Imaging Technologies) was utilized to capture luminescence signals with a f/1 camera lens aperture, binning at 4 and 5 min exposure time. Mice were imaged at various time points between 1 and 24 days post inoculation. To determine the inoculum doses, spirochetes were counted using a Petroff–Hausser counting chamber and verified by the number of colony-forming units plated in solid BSK medium. All inocula were PCR verified to contain all expected *B.*

burgdorferi plasmids as previously described (54). Immediately following the final *in vivo* imaging system (IVIS) reading time point, mice were sacrificed and ear and bladder tissues were cultured for spirochete reisolation as described (55), and all mice were confirmed positive for infection. Any background luciferase signals detected in the mice inoculated with *B. burgdorferi* carrying the promoterless luciferase gene were subtracted out of the readings.

RESULTS

5' End Identification across the *B. burgdorferi* transcriptome

IVET-based approaches are powerful methods to identify transcriptionally active sequences, annotated as *in vivo expressed (ive)* sequences, in an environment of interest (34). Previously our lab developed IVET for BbIVET to identify putative promoters that are active during a murine infection (29). This approach exploited the use of a promoterless nicotinamidase, *pncA*, a gene required for *B. burgdorferi* survival in the mammalian host, and a randomized, fragmented *B. burgdorferi* genomic library (Supplementary Figure S1). The promoter trap system, after screening through a mouse model of *B. burgdorferi* infection, revealed 233 transcriptionally active sequences (Supplementary Table S2), herein referred to as *B. burgdorferi in vivo expressed sequences (Bbives)*. These putative promoters were sufficient to drive expression of *pncA* thereby restoring infectivity to a *B. burgdorferi* mutant lacking the essential gene. The design of the BbIVET approach did not uniquely distinguish promoters that are specifically active in the mammalian host, and a subset of these are likely active both in culture and during infection. Further, this approach did not include assessment of *B. burgdorferi* transcripts that are produced during the tick phase of the enzootic cycle. To discover candidate genes that are expressed during mammalian infection, these sequences were mapped to annotated ORFs in the *B. burgdorferi* B31 genome under the parameter that a *Bbive* must be found within 300 nts upstream of an annotated start codon. A total of 91 *Bbives* fell into this category; whereas unexpectedly, the remaining 61% of the sequences discovered through BbIVET mapped to genomic locations internal, antisense or intergenic to ORFs (Supplementary Table S2). Furthermore, given the highly repetitive nature of regions of the *B. burgdorferi* genome, 34 *Bbives* exactly mapped to multiple genomic locations. To indicate these instances, decimal delegations were assigned to non-specific *Bbives* to indicate every possible genomic location that the sequence may have derived from (e.g. *Bbive149.1* maps to lp25 and *Bbive149.2* to lp36 but is the same nucleotide sequence; Supplementary Table S2).

To validate the non-ORF associated promoters, discovered through BbIVET and to gain a deeper overall understanding of the *B. burgdorferi* transcriptome, we identified genome-wide TSSs. Utilization of a 5' end RNA-seq protocol (5'RNA-seq) defined the TSSs and 5' processed ends of two biological replicates of *B. burgdorferi* clone B31 A3 grown to log phase in culture. Native RNA transcripts contain a triphosphate at the 5' end, whereas those that are endogenously processed or degraded have a monophosphate or hydroxyl group at the 5' end. These characteristics were

Table 1. Comparison of 5' RACE/primer extension 5' end determination and 5'RNA-seq identified TSSs in *B. burgdorferi* B31

Gene	ORF annotation ^a	5' RACE/primer extension 5' end position	Reference	5'RNA-seq TSS position	Avg. TAP+ read count ^b	Avg. TAP- read count ^c	TAP+:TAP- Ratio	Nucleotide position difference (nts) ^d
<i>ospA</i> ^e	BB_A15	9421	(94)	9421	19 421	1407	13.8	0
<i>chbC</i>	BB_B04	3849	(95)	3849	1693	28.5	59.4	0
<i>bb0360 operon</i>	BB_0360-0364	368 456	(71)	368 456	3941.5	123.5	31.9	0
antigen IpLA7	BB_0365	374 265	(96)	374 190	1097.5	172.5	6.4	75
<i>cheYI operon</i>	BB_0551	561 955	(97)	561 958	1433	55.5	25.8	3
<i>bbb22</i>	BB_B22	19 338	(78)	19 336	3020.5	160.5	18.8	2
<i>bbb23</i>	BB_B23	21 082	(78)	21 080	1609	59.5	27.0	2
<i>bpur</i>	BB_0047	46 423	(98)	46 423	191	60	3.2	0
<i>bdrF2</i> operon	BB_G29	24 469	(99)	24 347	222	11	20.2	122
	BB_G31	26 453		None ^f	N/A ^g	N/A	N/A	N/A
	BB_G33	28 014		28 017	293.5	25.5	11.5	3

^a*B. burgdorferi* gene annotations with one letter code signifying plasmid amplicon (50,90).

^bAverage normalized read counts from two biological replicated 5'RNA-seq TAP+ libraries, for a given TSS.

^cAverage normalized read counts from two biological replicated 5'RNA-seq TAP- libraries, for a given TSS.

^dDifferences in TSS positions from 5' RACE/primer extension compared to 5'RNA-seq.

^eThe two previously published TSSs for the *ospC* gene were not included, as these data were acquired using a *B. burgdorferi* strain other than B31 (100–102). Nonetheless, the 5'RNA-seq defined TSS for *ospC* was found to be located one and four nucleotides away from the two previously defined sites of transcription initiation.

^fNo TSS was identified within 300 nucleotides of BB_G31 ORF.

^gNot applicable.

exploited in our 5'RNA-seq protocol to discriminate between 5' ends. Samples were either treated with or without TAP during the library preparation. RNA-seq libraries with TAP treatment captured all RNA 5' ends; whereas, the TAP- libraries captured endogenously processed or degraded 5' ends (Supplementary Figure S1).

Illumina sequencing resulted in 265 million, 50 bp single-end reads from across all four libraries, ranging from 60 to 70 million reads per library. This theoretically corresponds to a total genomic coverage of about 1900–2200X. Due to the highly repetitive nature of some regions of the *B. burgdorferi* genome, reads that were not uniquely mapped to a single genomic location were removed. This resulted in 23–42 million reads (749–1388X coverage) for the main analysis. The 5' ends were then called across libraries and categorized based on the TAP+ enrichment of TSSs, which discovered 6042 potential TSSs and 30 716 processing and/or degradation events (Supplementary Tables S3 and S4). An online interactive interface is available to search the 5'RNA-seq data at www.ucf.edu/research/interactive-genomics/lyme-disease.

Examination of tRNA loci provided validation of our TSS and processed-end calling method. 5' end processing is critical for tRNA maturation (56) and as expected both TSSs and 5' processed ends were detected for tRNA transcripts (Supplementary Table S3 and S4). Furthermore, TSSs identified by 5'RNA-seq were compared to *B. burgdorferi* TSSs that were determined by 5' RACE or primer extension. The 5'RNA-seq identified TSSs were found to be within three nucleotides of 70% of the previously described TSSs in *B. burgdorferi* strain B31 (Table 1). Furthermore, the 5'RNA-seq library preparation protocol used herein was also performed in *E. coli*. These data were compared to *E. coli* TSSs identified by Thomason *et al.*, (2015), which used an independent enzyme, terminator 5'-phosphate-dependent exonuclease for TSS characterization

by 5' end RNA-seq (42). A majority of the TSSs called in our *E. coli* data set were consistent with the TSSs identified by Thomason *et al.* (manuscript in preparation, I.B., M.L. and R.S.). Together these data provide support for the robustness of our 5'RNA-seq method.

5' End identification in repetitive genomic regions

Although all of the data discussed herein are derived from the uniquely mappable portions of the B31 genome, we acknowledge that there may be a biological interest in *B. burgdorferi* genomic regions that contain repetitive sequences. In addition, it is possible that the exclusion of such sequences from our analysis may have affected the identification and categorization of the TSSs and processed 5' ends, both of which, as will be detailed in the following section, were highly dependent on the local genomic and transcriptional context. Therefore, we added for reference, an additional analysis of the 5'RNA-seq library that included the 5' nucleotide reads that mapped to repetitive regions and therefore had a mapping quality score of zero (MQ0). We analyzed these data to determine TSSs as described above and provide the results in Supplementary Table S5.

TSS classification

TSSs were categorized relative to their orientation to annotated sequences through a systematic classification assignment scheme. Because annotated sequences can lie adjacent, divergent or convergent and often in close proximity to one another, our classification scheme did not uniquely sort TSSs into single categories, similar to previously applied approaches that used automated TSS classification algorithms (40,42). Therefore, a TSS could be assigned multiple classifications (Figure 1A). Accounting for overlaps among categories (i.e. counting each TSS for all categories to which it was assigned), 12% of the TSSs were classified as primary,




Figure 1. Genome-wide identification and characterization of *B. burgdorferi* transcription start sites (TSSs). RNA was isolated from log phase *B. burgdorferi* clone B31 A3, and treated with and without TAP (tobacco acid phosphatase). (A) Schematic classification of the 6042 TSSs relative to the genome organization. Circled numbers indicate TSSs for each category. The maximum nucleotide distances from the 5' and/or 3' of annotated sequences, shown as black arrows, for a particular category of TSS are indicated in red. (B) Graphical representation of the TSS classifications. as, antisense; o, orphan; p, primary; s, secondary; i, internal. (C) Nucleotide frequency at the -100, -1, +1 (TSS) and -1 nucleotide positions. A, adenine, T, thymine, G, guanine, C, cytosine. (D) Consensus motif for promoter regions upstream of primary TSSs. The nucleotide sequences from -40 to +1 of the 321 identified primary TSSs were analyzed by MEME 4.11.2. (E) Distribution of 5' untranslated regions (UTR) lengths among uniquely classified primary and secondary TSSs. The data are shown as the percent of mRNA sequences with a 5' UTR of each bin length. 0–10 nucleotides (red bar), bin size of 20 nucleotides, where the number shown is the middle length in each bin (black bars). (F) Consensus ribosome binding motif for uniquely classified, primary 5' UTRs. MEME 4.11.2 was used to analyze UTR sequences ranging from 10–293 nts in length for a conserved motif, which was found on average to begin 8 nts upstream of the annotated start codon. (G) Northern blot analyses validate a long 5' UTR. Total RNA was extracted from mid-log phase spirochetes and separated by denaturing formaldehyde–agarose gel, blotted to nylon membranes and probed with ³²P-labeled complementary probes, indicated by red and black boxes. Genomic context of ORFs BB_0240–BB_0243 (wide black arrows), the primary TSS (green bent arrow), putative transcripts and their position on the Northern blot (broken line, green arrows and marked with designated symbol) are indicated. Marker sizes in nucleotides are indicated to the left of each blot.

10% as secondary, 13% as antisense, 63% as internal and 2% as orphan (Figure 1B).

Unique initiating nucleotide usage for *B. burgdorferi* transcription

Purine nucleotides are typically the most common initiating nucleotide in bacteria (57,58). Surprisingly, in *B. burgdorferi* cytosine had a similar frequency as adenine at the +1 position for all TSSs identified in this study. The individual nucleotide frequencies were measured at 32.2% A, 15.2% T, 20.9% G and 31.6% for TSSs despite the A/T-rich (71.8%) nature of the genome (Figure 1C and Supplementary Figure S5). As a comparison, the nucleotide frequency at the -100 position was found to be 72.2% A + T (Figure 1C). This is consistent with the average nucleotide frequency of 70.5% for all positions 100 nucleotides upstream and downstream of the TSSs (Supplementary Figure S5A and B). TSSs were found most commonly flanked by a thymine at the -1 position (69.7%) and an adenine at the +2 position

(51.2%) (Figure 1C). Internal TSSs constitute the majority of the TSSs identified and analysis among different TSS categories separately demonstrated that only the internal TSSs have the higher G + C nucleotide frequency at the +1 nucleotide. The primary, secondary, antisense and orphan +1 nucleotide frequencies were similar to the genome-wide average (Supplementary Figure S5C–G).

Identification of σ^{70} motifs in TSS promoter regions

As both a means of validation and Pribnow box discovery, sequences containing the +1 nucleotide and corresponding 40 nucleotides upstream of all of the 321 unique primary TSSs (Figure 1A) were analyzed for conserved sequence motifs using MEME 4.11.2 (59). Due to the abundance of A/T nucleotides in the *B. burgdorferi* genome, a training set of 100 000 random 41 nucleotide subsequences from the B31 reference genome was selected for a background control. Not surprisingly, given that the 5'RNAseq library was generated from logarithmic phase bacteria, which were ex-

pected to be expressing predominately sigma 70-dependent transcripts, we detected a 29 bp motif containing a canonical Pribnow box (beginning on average at the -6 position), in its consensus sequence, upstream of 320 of the 321 primary TSSs (Figure 1D). However, these sequences lacked strong conservation at the -35 region, which is consistent with observations made in other bacteria (35,42,57). A similar conserved Pribnow sequence was identified upstream of 88 of the 162 secondary TSSs (54.3%) and 656 of the 734 antisense TSSs (89.4%) (data not shown); these sequences also lacked a conserved -35 region. In contrast, no conserved sequence motifs were detected upstream of the 3568 unique internal TSSs. However, further analysis of internal TSSs with high TAP+ read counts (greater than 500) revealed a similar conserved Pribnow box in 109 out of 266 (41.0%) of these sequences (data not shown).

Leaderless and long UTRs

Depending on their size and secondary structure, 5' untranslated regions (UTRs) may contain important RNA regulatory elements (60–62). Mechanisms of *cis*-regulatory RNAs have yet to be explored in *B. burgdorferi*. To identify ORFs that might be controlled by *cis*-regulatory RNAs we characterized the lengths of the 5' UTRs associated with uniquely classified primary and secondary TSSs that were only assigned to a single annotated transcript (on occasion, due to small ORFs, a primary or secondary TSS was assigned to multiple ORFs and these were excluded from the analysis) (Supplementary Table S6). Our data indicated that the median 5' UTR length in *B. burgdorferi* is ~ 36 nts (Figure 1E), which is consistent with what has been determined for other bacterial species (35,36,57,63,64). Approximately 19% of the 5' UTRs analyzed were less than 10 nts in length and a 29% subset of these short sequences represented leaderless transcripts with a 5' UTR length of zero (Figure 1E). Approximately 17% of the 5' UTRs were found to be between 100 and 293 nts in length, suggesting that these sequences may harbor additional regulatory functions (Figure 1E). The 5' UTR sequences greater than 10 nts in length, were also analyzed for a ribosome binding site motif using MEME as previously described (59). A conserved A/G rich, 11 nt sequence was found in 97.6% of the UTRs analyzed. Furthermore, this motif was primarily located near the ORF, with a median distance of 8 nts upstream of the annotated starts of translation (Figure 1F). Northern blot analyses validated the presence of the 195 nt 5' UTR upstream the four-gene *gfp* operon. Northern blot probes specific to the BB.0240 UTR (red probe) and coding (black probe) regions, both revealed a ~ 4500 nt transcript (Figure 1G). These data demonstrated the presence of a large transcript that included the 195 nt 5' UTR, consistent with the predicted combined size of the ORFs contained in *gfp* operon (4300 nts) and several putative internal transcripts. The UTR probe also detected a small RNA transcript (~ 195 nts), consistent with the size of the 5' UTR.

Correlating TSSs with BbIVET putative promoters

The global identification of *B. burgdorferi* TSSs not only contributed understanding to the *B. burgdorferi* transcriptome but resulted in a 5' end map of the annotated and




Figure 2. *B. burgdorferi* in vivo expression technology (BbIVET)-identified sequences with associated TSSs. (A) Schematic representation of BbIVET associations with 5'RNA-seq TSSs. Brackets designate the parameters for the association. Relative orientation of the genome region (wide black bar with white arrows), *Bbive* sequence (thin black arrow) and TSS (orange bent arrow) are indicated. The minimum and maximum *Bbive*-TSS association distances were defined as 20 nts from the 5' end and 6 nts from the 3' end of a *Bbive* sequence. (B) Categorization of *Bbives* that associate with 5'RNA-seq TSSs.

un-annotated transcripts expressed by the spirochete during growth in culture, which could provide further insight into the sequences recovered from BbIVET. Of the 233 unique *Bbive* sequences, 119 were found to be associated with culture-expressed TSSs (Figure 2A and Supplementary Table S2), suggesting that these promoters are active both in culture and during infection. *Bbive*-TSSs were classified into the following categories: 39 primary, 37 secondary, 159 internal, 19 antisense and 2 orphan (Figure 2B). In some cases multiple TSSs were associated with the same *Bbive* and some TSSs were classified into multiple categories. Together these data validated the significance of the *Bbive* sequences located in previously un-annotated genomic positions. Moreover, the comparative analysis revealed that 114 *Bbives* were not associated with any detected TSS from the in culture derived 5'RNA-seq data set, suggesting that these sequences may be primarily active during murine infection.

Validation of BbIVET-associated transcripts

Fifty-one percent of the *Bbives* were associated to TSSs discovered by 5'RNA-seq, indicating that these transcripts are expressed both in culture and in the mammalian host. Although some of these sequences may provide housekeeping functions, the finding that a large percentage of the *Bbives* fall into this category does not exclude the possibility that these promoters, and the transcripts that they control, con-

tribute to *B. burgdorferi* pathogenesis. Indeed 5'RNA-seq identified TSSs for a number of genes known to be critical for *B. burgdorferi* infectivity including *ospC*, *bosR* and *vlsE* (Supplementary Table S3) (5). Validation of a subset of *Bbive*-TSSs was carried out using Northern blot analyses and promoter fusion assays. *Bbive45* is an intragenic sequence that maps within the chromosomal gene BB_0370 and is associated with an internal TSS and proximal to two processed 5' ends (Figure 3A and Supplementary Table S2). Northern blot analysis using an oligonucleotide probe complementary to the sequence downstream of both the internal TSS and the processed 5' ends revealed an ~500 nt transcript, which could be attributed to one or more of these 5' ends (Figure 3B, black probe). In contrast, this transcript was absent when a probe targeted against sequence upstream of the three 5' ends was used (Figure 3B, red probe). Of note, bacterial transcriptomes are complex as a result of compact gene organization as well as overlapping and antisense orientated transcript expression (65). As expected due to this complexity, additional transcripts were also detected in these Northern blots, which may represent the ~1.2 kb BB_0370 ORF itself and/or additional read-through transcripts initiated further upstream.

The DNA sequence located directly upstream of a TSS is expected to function as a promoter and initiate transcription, while the sequence directly upstream of a processed end should not. To validate the ability of 5'RNA-seq to distinguish TSSs and processed 5' ends, as well as confirm the ability of *Bbive45* to function as a promoter, the promoter activities of sequences upstream of the internal TSS or the processed 5' ends in BB_0370 were measured using luciferase transcriptional fusions. Upstream regions of the internal TSS or the dominant processed 5' end were cloned in front of the promoterless, *B. burgdorferi* codon optimized firefly luciferase gene, in the *B. burgdorferi* shuttle vector pJSB161 (53). This generated promoter fusions *Bbive45:luc* and *Bbive45proc:luc*, respectively (Figure 3A). The *Bbive45:luc* fusion, which carries the putative promoter for the internal TSS of interest, demonstrated a significant increase in luciferase activity relative to the promoterless reporter gene (Figure 3C). These data indicated that this sequence functions as a promoter albeit to a lesser extent than the *B. burgdorferi* promoter for the constitutive flagellar gene *flaB*. In contrast, the *Bbive45proc:luc* construct did not exhibit any detectable promoter activity (Figure 3C). Together these data support the ability of 5'RNA-seq to identify and distinguish TSSs and processed 5' ends and confirm a BbIVET identified sequence functions as a promoter.

The luciferase transcriptional fusion validation approach was expanded to a larger subset of *Bbive*-TSSs. DNA including the *Bbive* sequence to the TSS (Figure 3D), for 5 *Bbives* were fused to luciferase in pJSB161. *Bbive12*, *74*, *76*, *86* and *203* were found to be associated with TSSs, which were classified as primary, internal or antisense (Table 2). The activities of the *Bbive* promoters were compared to that of the known constitutive *flaB* promoter and two environmentally regulated control promoters, *ospAp* and *ospCp*. The genes encoding for the critical virulence outer surface proteins, *OspA* and *OspC*, demonstrate in-

verse patterns of expression during the infectious cycle of *B. burgdorferi* (8–12). The *ospA* gene displays low expression in the mammalian host and high expression in culture and the unfed tick. In contrast, *ospC* exhibits high expression during mammalian infection and low expression in culture (29) and the unfed tick. All five *Bbive*-TSS promoter fusions resulted in significant levels of luciferase activity compared to the promoterless control (Figure 3E). Furthermore, the promoter activities of all of the sequences except for *Bbive74* were found to be significantly higher than that of the mammalian induced *ospCp*. Although 5'RNA-seq measures steady state levels of RNA transcripts and promoter fusions quantify amounts of RNA polymerase activity, there was a correlative trend of promoter strength to 5'RNA-seq read counts. The greater the average TAP+ read count determined by 5'RNA-seq, the greater the average relative luciferase units measured by promoter fusion (Table 2). Overall these data provided experimental support for *Bbive*-TSS defined promoters across a diversity of annotated and un-annotated transcripts.

Activity of novel *B. burgdorferi* promoters during murine infection

Luciferase-promoter fusion constructs can be used to assay promoter activity in real time during an active infection. Therefore, the activities of the six *Bbive*-TSS defined promoters were examined during murine infection using IVIS. Spirochetes carrying the individual *Bbive:luc* fusions (Table 2) or the promoterless, *flaBp*, *ospAp* or *ospCp* control constructs were inoculated intraperitoneally into groups of three mice at a dose of 1×10^5 bacteria. Bacterial bioluminescence was assessed in the live infected mice, following delivery of D-luciferin, by photon emission using IVIS over a 10 day time course (Figure 4). The 10-day time point was experimentally determined to have the highest sensitivity of detection using *B. burgdorferi* carrying the luciferase gene driven by the constitutive promoter, *flaBp* (Supplementary Figure S6). *B. burgdorferi* infection of all mice was confirmed by reisolation of spirochetes from tissues. Mice infected with spirochetes harboring the promoterless luciferase construct (pJSB161) served as the control for background levels of bioluminescence. The *ospAp* and *ospCp* luciferase fusion activities in the mouse were as expected based on their known patterns of expression, off and on, respectively (Figure 4) (8–12). All *B. burgdorferi* clones carrying the *Bbive* luciferase fusions, with the exception of *Bbive74*, demonstrated luciferase activity at day 7 and/or day 10 post-infection (Figure 4), but not at earlier time points (data not shown). Variations in the levels of bioluminescence detected for each *B. burgdorferi* clone at the two time points likely reflected sequence-and/or time-dependent regulation of the *Bbive*-TSS promoters during infection. The *Bbive74:luc* fusion demonstrated low but significant promoter activity in spirochetes grown in culture (Figure 3E) but no detectable bioluminescence in the mouse (Figure 4). Cumulatively, these data demonstrate culture and mouse infection activity of a panel of *B. burgdorferi* promoters defined by BbIVET-identified sequences and the associated TSSs for a diversity of transcript categories. Furthermore, these data show that global TSS identification by




Figure 3. Validation of BbIVET-associated RNA transcripts. (A) Deep-sequencing screen shot for a *Bbive*-internal TSS, displaying only the sequenced 5' nucleotide, of overlaid biological replicates treated with (TAP+) and without (TAP-) tobacco acid pyrophosphatase. Read count ranges are shown in the upper left of each frame. The chromosome nucleotide coordinates, relative orientation of the BB_0370 ORF (wide black bar), *Bbive45* sequence (thin black arrow), internal TSS (blue bent arrow), processed 5' ends (scissors), putative transcripts (broken line arrows), Northern probe locations (black and red boxes) and luciferase fusion regions (brackets) are indicated. The predicted transcripts of interest are marked with an asterisk. (B) Northern blot analyses of the *Bbive45* internal TSS, as described in the Figure 1 legend. Probes located upstream (red) and downstream (black) of the putative internal TSS, are indicated. Marker nucleotide sizes are indicated to the left of the blots. (C) *Bbive45* promoter activity and specificity. *B. burgdorferi* clones harboring specific promoter fusions were grown to mid-log phase, and incubated with 750 μ M D-luciferin. Relative luciferase units (RLU) were normalized to cell density by OD₆₀₀. Data represent the mean \pm SD from three biological replicates shown in log scale and were analyzed relative to pJSB161 with the two-tailed Student's t-test. Unless otherwise indicated all fusion constructs demonstrated significantly greater RLU than the promoterless control, pJSB161 ($P \leq 0.01$). n.s., not significantly greater RLU relative to pJSB161. (D) Schematic representation of *Bbive* luciferase fusions. The bracket designates the sequence selected for promoter fusion to luciferase in pJSB161. Relative orientation of the genome region (wide black bar with white arrows), 5' boundary of *Bbive* sequence (orange line) and TSS (orange bent arrow) are indicated. (E) A variety of *Bbives* with associated TSSs have promoter activity in culture. Spirochetes containing control promoters (*flaBp*, *ospCp* and *ospAp*) and specific *Bbives*, fused to luciferase, were grown to mid-log phase, and analyzed as described above.

5'RNA-seq provides significant insight into the *B. burgdorferi* transcriptome that validates un-annotated sequences discovered through BbIVET.

Unlike other pathogen transcriptome studies (66–68) that benefit from direct collection of bacterial cells from infected animals for RNA-seq, low spirochete numbers present during a *B. burgdorferi* infection requires innovative approaches to identify *B. burgdorferi* transcripts that are expressed in the mammalian environment. Comparative analysis of the BbIVET and 5'RNA-seq data sets revealed 114 *Bbives* with no associated culture-specific TSSs (Supplementary Table S2). Furthermore, considering the MQ0-analysis (Supplementary Table S5) only 5 of the 114 *Bbives* contain un-mappable TSSs. These sequences harbored sufficient promoter activity to be captured in the BbIVET screen, suggesting they may control transcripts that are specifically expressed during murine infection. Therefore, we generated luciferase promoter fusions of *Bbive36*, *158*, *161*, *175* and *252* that had no associated TSS by 5'RNA-seq. In addition, we tested *Bbive277*, which had a low-coverage

TSS. For these experiments the entire *Bbive* sequence that was originally recovered from BbIVET (Supplementary Table S2) was fused to luciferase and evaluated for luminescence both in culture and during murine infection. Similar to the *ospC* promoter, *Bbive277*, *36*, *158* and *252* exhibited promoter activity in culture above that of the promoterless control but significantly less than that of the *flaB* and *ospA* promoters (Figure 5A). These data demonstrated that these promoters display activity in culture despite the lack of associated TSSs. However, no significant promoter activity was detected for *Bbive161* or *Bbive175* during growth in culture (Figure 5A). To assess the promoter activities of these *Bbive* sequences in the mammalian host, groups of mice were infected with 1×10^5 spirochetes carrying each luciferase fusion construct and evaluated for luminescence using IVIS. Three of the six *Bbive* sequences, *Bbive277*, *158* and *252*, displayed detectable luciferase activity at days 7 and 10 post infection (Figure 5B and data not shown), suggesting that these promoters are active during murine infection, albeit at a levels lower than that of the *flaB* and *ospC*

Table 2. BbIVET-associated TSS read counts and luciferase promoter fusion relative activity

Promoter ^a	Replicon	TSS Position ^b	Strand	Category ^c	Category Details (Annotation) ^d	Avg. TAP+ Read Count ^e	AVG RLU ^f
<i>flaBp</i>	chr	148715	-	primary	P:BB.0147 (flagellin)	9.39E+05	1.19E+06
<i>ospAp</i>	lp54	9421	+	primary	P:BB_A15 (<i>ospA</i> , outer surface protein A)	1.94E+04	2.31E+05
<i>ospCp</i>	cp26	16883	+	primary	P:BB_B19 (outer surface protein C)	37.5	134.4
<i>Bbive12^a</i>	chr	174219	-	internal, primary	I:BB.0172 (von Willebrand factor type A domain-containing protein), P:BB.0171 (hypothetical protein)	1.42E+04	1.07E+04
<i>Bbive45</i>	chr	379813	-	internal	I:BB.0370 (<i>tyrS</i> , tyrosine-tRNA ligase)	243	663.1
<i>Bbive74</i>	chr	647833	+	antisense	A:BB.0620 (<i>beta</i> -glucosidase)	194	85.9
<i>Bbive76</i>	chr	659711	+	antisense	A:BB.0629 (PTS system fructose-specific transporter subunit IIABC)	362	1.62E+03
<i>Bbive86</i>	chr	746049	+	internal, primary	I:BB.0709 (hypothetical protein), P:BB.0710 (<i>dnaG</i> , pseudo)	1.58E+03	4.66E+03
<i>Bbive203</i>	chr	146579	-	internal, primary	I:BB.0146 (glycine/betaine ABC transporter ATP-binding protein), P:BB.0145 (glycine/betaine ABC transporter permease)	6.71E+03	1.12E+04

^aControl promoters and *Borrelia burgdorferi* *in vivo* expressed sequence identification numbers.

^bReplicon specific nucleotide position of 5'RNA-seq identified TSS.

^cTSS category assignment.

^dAnnotation of the TSS associated ORF (50,90), where single letter abbreviations indicate the annotation for the TSS category.

^eAverage normalized read counts from 5'RNA-seq TAP+ libraries, for a given TSS.

^fPromoter activity for each TSS, as determined by luciferase activity in RLU, for spirochetes grown to log phase in liquid culture.

promoters at these time points of infection. None of the tested *Bbive* sequences were found to be specifically active in the mammalian host, as *Bbive 277*, *158* and *252* demonstrated promoter activity in culture (Figure 5A). However, these *Bbive* sequences appear to represent promoters for novel un-annotated RNA transcripts. *Bbive158* is located internal to the annotated pseudo gene BB_K02a on lp36. *Bbive252* lies antisense to the hypothetical protein coding gene BB_F14 on lp28-1. *Bbive277* maps internal to chromosomal gene BB.0319, which encodes a riboflavin binding protein that may be a component of a riboflavin ABC transporter (69). Future studies are focused on elucidation of the functions of these transcripts in *B. burgdorferi* biology. For the sequences that demonstrated no detectable promoter activity in this assay, further analysis is required to distinguish between the possibility that these *Bbive* sequences lack promoter activity completely or that the amount of transcription driven by these sequences falls below the threshold of sensitivity by IVIS. In sum, our data provide the first evidence of *B. burgdorferi* expression of antisense and intragenic transcripts in the mammalian host environment.

DISCUSSION

A global understanding of the transcriptome of a pathogen in environments of interest can provide key insight into patterns of gene expression and possible modes of gene regulation, which are critical for elucidating molecular mechanisms of pathogenesis. *B. burgdorferi* requires coordinated mechanisms of gene regulation to survive throughout its enzootic life cycle (6); however, the molecular events that contribute to this process, particularly during mammalian infection have remained largely unknown. Clearly the mechanisms of *B. burgdorferi* adaptation for survival in the tick vector are critical for environmental persistence as well as pathogenesis of the spirochete. Nonetheless, the work presented herein focused on elucidation of *B. burgdorferi* transcripts expressed in the mammalian host using a

mouse model of infection. We overcame the challenges of the paucity of spirochetes present in infected mouse tissues to direct transcriptome analysis through BbIVET (29). BbIVET identified 233 unique putative promoter sequences, a majority of which mapped to un-annotated antisense and intragenic positions in the genome. The BbIVET library likely did not provide complete coverage of the *B. burgdorferi* genome. However, there were several instances where we recovered the same *Bbive* from multiple mice and multiple, unique *Bbives* were recovered from the same mouse (29). Therefore, we are confident that BbIVET allowed discovery of unique and novel promoter regions across the chromosome and plasmid replicons, which could potentially contribute to Lyme disease pathogenesis. To gain further insight into the significance of the *Bbive* sequences we applied a genome-wide 5' end RNA-seq approach using *B. burgdorferi* grown in culture. Transcriptome complexity and experimental technicalities pose additional challenges to the direct measurement of strand-specific RNA transcripts by conventional methods such as RT-qPCR. Therefore, we utilized luciferase transcriptional fusions, which provided a unique approach to evaluate promoter activity of novel *B. burgdorferi* transcripts during an active infection. Comparative analysis of BbIVET and 5'RNA-seq has validated 5' ends, characterized a variety of categories of RNA transcripts and discovered novel transcripts that contribute to the *B. burgdorferi* transcriptome during mammalian infection.

5' end RNA-seq has been shown to be a valuable transcript discovery tool for a variety of organisms, and the differential application of TAP, or similar enzymes, to globally define TSSs and processed 5' ends has been comprehensively validated through many independent studies (35,37,42,57). Although 5' ends may be inferred from total RNA-seq data (70), unlike 5'RNA-seq, these studies are unable to distinguish between TSSs and processed 5' ends and therefore only provide estimations of transcript bound-




Figure 4. Culture-expressed *Bbive*-TSSs demonstrate activity in the mammalian host. C3H/HeN mice infected intraperitoneally with 1×10^5 *B. burgdorferi* containing promoterless pJSB161, control promoters (*flaBp*, *ospCp* or *ospAp*) or specific *Bbive* luciferase fusions as indicated (left). Mice were injected intraperitoneally with 150 mg/kg D-luciferin 7 and 10 days post infection and imaged with the IVISTM 50 Imaging System (IVIS) using a 5 min exposure. Images were normalized to the same p/s range of 1.73e4 to 1.128e5 and displayed on the same color spectrum scale (right). Data are representative of two independent biological replicates. asTSS, antisense TSS; p/iTSS, primary or internal TSS; iTSS, internal TSS.

aries (35). Our application of 5'RNA-seq provides a snapshot of 6042 unique, potential TSSs across the *B. burgdorferi* genome during log phase growth in culture. Our 5' end identification method was designed to exclude excessive sequencing background noise, but still report the 5' ends for a variety of transcripts in 5'RNA-seq that have low expression in culture, such as the mammalian-induced *ospC* gene.




Figure 5. Novel *B. burgdorferi* RNA transcripts expressed during murine infection. (A) A subset of *Bbives* that lack or have low read count associated TSSs demonstrate low promoter activity in culture. *Bbive* sequences were fused to luciferase in pJSB161 and measured for luciferase activity, as described in Figure 3 legend. Data represent the mean \pm SD from three biological replicates shown in log scale and were analyzed relative to pJSB161 using the two-tailed Student's *t*-test. Unless otherwise indicated all fusion constructs demonstrated significantly greater RLUs than the promoterless control, pJSB161, ($P \leq 0.01$). n.s., not significantly greater RLU relative to pJSB161. (B) Bioluminescence of *Bbive* sequences in the murine host. C3H/HeN mice infected intraperitoneally with 1×10^5 *B. burgdorferi* containing controls and specific *Bbive* luciferase fusions, analyzed by IVIS as described in Figure 4 legend. Symbols indicate specific controls for each time point. Data are representative of two biological replicates. Note that the same color spectrum scale is used between figures.

We acknowledge that bias in the library preparation at either the 5' linker ligation or the amplification steps, or unintentional 5' phosphate loss during manipulation of the RNA prior to sequencing could potentially lead to inaccuracies in the classification of 5' ends, particularly for sequences with TAP+:TAP- ratios close to the 2-fold enrichment cut off. Degradation of RNA during manipulations for 5' end library preparations likely contributed, at least in some subset, to the high number of processed 5' ends reported herein. It is also possible that in some instances a

TSS was not captured in our libraries due to a high rate of mRNA turnover. Here, we provided several means of validation of 5' end identification in *B. burgdorferi*. Initial comparison of 5' RNA-seq data to published 5' RACE- or primer extension-defined TSSs demonstrated high correlation in the data. This is consistent with the 87% correlation reported for a similar comparison performed in *Helicobacter pylori* (35). It is possible that highly structured regions of the transcriptome may pose technical challenges to 5' RACE and primer extension as well as 5' RNA-seq, which may contribute to the differences between the published TSSs and the 5' RNA-seq data. Additionally, some 5' RACE and primer extension approaches are unable to distinguish between TSSs and stable processed transcripts. Therefore, we provided bioinformatics evidence of conserved promoter elements upstream of the 5' RNA-seq identified TSSs as well as used promoter fusions and Northern blotting to further validate the 5' RNA-seq data.

As many 5' RNA-seq data sets have revealed in recent years, bacterial transcriptomes are rich in un-annotated sequences (65). 5' RNA-seq in *B. burgdorferi* led to the discovery of initiation sites for transcripts that span across, between, antisense and internal to annotated ORFs. Although TSS validation by Northern blot analysis may be obscured by transcriptional complexity, we have used multiple Northern blot probes targeting regions of interest to more confidently validate the presence of a transcript downstream of 5' ends. Furthermore, our results indicate that transcriptional complexity may confound transcript boundary analysis techniques such as reverse transcriptase-PCR that is used to amplify across annotated gene gaps for evidence of operons. For example, the 5' RNA-seq data identified additional putative primary TSSs within the recently described operons, BB_0360-BB_0364 (71), BB_0215-BB_0218 (72) and BB_0404-BB_0406 (73). These findings do not rule out the possibility that these gene clusters are co-transcribed, but suggest that multiple transcripts initiate within these loci that may not be detected by traditional methods. Indeed, sorting out exact transcript maps, particularly in complex annotated regions, proves complicated. Even more challenging, is definitive determination of the origin of transcription for the identified processed 5' ends. In these cases, we did not attempt to classify processed 5' ends based on location and rather only reported specific nucleotide positions of all instances. Future targeted experimental approaches are required to determine the TSS for each processed 5' end.

Principally 5' RNA-seq in *B. burgdorferi* was conducted to better understand and distinguish mammalian specific promoters discovered through BbIVET. However, in establishing this TSS map we discovered numerous novelties of *B. burgdorferi* transcription. Of most note, was the observation that adenine and cytosine demonstrated equivalent frequencies of occurrence as the initiating nucleotide for transcription at internal TSSs. It has been recognized that nucleoside triphosphate concentrations within the cell can dictate initiation of transcription based on the +1 nucleotide availability, as was first shown for ribosomal RNA (74). *B. burgdorferi* lacks the enzymes for *de novo* purine biosynthesis, and in turn must salvage these molecules from the host environment for nucleotide synthesis (75–77). Considering

the concentrations of available nucleotides and nucleotide precursors likely differ depending on the spirochete's immediate environment (54,76,78), nucleotide availability may serve as one fundamental mechanism of transcriptional regulation. Indeed, the identity of the transcription start site nucleotide and changes in intracellular ATP and GTP levels have been shown to critically alter gene expression during starvation in *Bacillus subtilis* (79).

We have demonstrated strong conservation of the classical Pribnow box among the promoter regions of the primary, secondary and antisense TSSs. Collectively, the internal TSSs lacked a conserved promoter sequence, similar to what has been documented for *Hfx. volcanii* (80), but in contrast to findings in other bacterial species (35,42). However, the analysis of 7.5% of internal TSS promoter elements with TAP+ read counts of greater than 500, demonstrated 41.0% with a conserved Pribnow box. These data raise the possibility that expression of the majority of the *B. burgdorferi* intragenic transcripts may be controlled by mechanisms that differ from known means of sigma 70-dependent regulation. Alternatively, it is possible that in some instances the spirochete RNA polymerase initiates off-target, in what has been referred to as pervasive transcription. However, this does not diminish the biological relevance of these events, as evolutionary pressures could result in the functional roles of such transcripts (81).

We identified 85 leaderless mRNAs, having a UTR length of less than 10 nts. Typically leaderless transcripts in bacteria are thought to be translated at low efficiency due to the absence of a canonical ribosome binding site (82). However, in *E. coli* under certain stress conditions specialized ribosomes, lacking the anti-Shine–Dalgarno sequence, have been shown to proficiently translate leaderless mRNAs (83). An abundance of leaderless transcripts have recently been discovered in the genomes of *Mycobacterium smegmatis* and *Mycobacterium tuberculosis* (36,41), which have been found to be translated as efficiently as leadered transcripts (41). While the majority of *B. burgdorferi* leaderless transcripts are annotated as hypothetical proteins, it is feasible that these sequences may be involved in stress adaptation or that ribosome recognition of leaderless mRNA targets in *B. burgdorferi* may occur by a yet-to-be described mechanism, as proposed for mycobacterial species (41). It is also possible that mis-annotation of an ORF and/or the presence of an alternative start codon could have resulted in inaccurate identification of a transcript as leaderless.

Cis-regulatory RNA elements, such as riboswitches and attenuators present in 5' UTRs, may control mRNA transcription and/or translation (84,85). To date, the only functionally characterized example of 5' mRNA regulation in *B. burgdorferi* is the mechanism of post-transcriptional regulation of the alternative sigma factor *rpoS* by the temperature induced *trans*-acting sRNA *dsrA* (86). No riboswitch mediated gene regulation mechanisms have been discovered in *B. burgdorferi*, and among all spirochetes only one example of a riboswitch has been described, a thiamine sensor in *Treponema denticola* (87). Several studies have investigated the contribution of cyclic-di-GMP, the second messenger and common riboswitch ligand, in *B. burgdorferi* environmental sensing (88,89). Recent data demonstrate that the four-gene (BB_0240-BB_0243) *glp* operon, involved in glycerol trans-

port and metabolism (89–91), is regulated by cyclic-di-GMP (c-di-GMP) (88,89,92). By Northern blotting we validate the presence of a long UTR in the *glp* operon. Additionally, the UTR probe alone revealed a ~200 nt transcript. These data suggest the presence of a terminated transcript within the 5' UTR of the *glp* operon, which may indicate a *cis*-regulatory RNA element (62) and provide support for the notion that long 5' UTR sequences in *B. burgdorferi* may harbor additional regulatory information.

Of the 233 total unique *Bbive* sequences, 119 associated with 5'RNA-seq identified TSSs. This group is comprised of transcripts expressed both in culture and the mammalian host, some of which may be *B. burgdorferi* mammalian infection-induced and/or infection-essential RNA species. Among these transcripts, there are at least five genes that have been previously shown to be required for *B. burgdorferi* pathogenesis through a signature-tagged mutagenesis screen, including BB_0145 (27). Herein, we demonstrated that the *Bbive203*-TSS promoter associated with infection-relevant BB_0145 is active both in culture and during infection. These data highlight the importance of further analysis of these transcripts despite the finding that their expression is not limited to the mammalian host environment. Only one *Bbive*-TSS, *Bbive74*, failed to demonstrate promoter activity during infection. This TSS was located only 29 nts downstream the 5' end of the 125 bp *Bbive74* sequence. Based on the cloning strategy of promoter fusions for *Bbive*-TSSs, 96 bp of *Bbive74* were not tested for promoter activity and could conceivably contain an infection-specific promoter and TSS. Alternatively, the activity of this transcript in the mouse could fall below the level of detection by IVIS.

A subset of *Bbives* are associated with low-coverage TSSs, as determined by 5'RNA-seq. In fact, 53 *Bbive*-TSSs displayed an average TAP+ read count less than 50. Herein we demonstrate that *Bbive277*, which has an average TAP+ read count of 44.5 and just above the threshold cutoff of calling TSSs in 5'RNA-seq, is active during infection. Some portion of these in culture, lowly expressed *Bbives* may be induced in the mammalian host. For instance, the primary TSS for the mammalian infection specific *ospC* mRNA had an average TAP+ read count of 37.5 in culture, and demonstrated low promoter activity in culture, but strong promoter activity during murine infection. Notably, exact quantifications of these instances cannot be empirically determined by the *in vivo* imaging approaches reported herein.

Comparative analysis of the BbIVET and 5'RNA-seq data sets identified 114 *Bbives* that did not associate with culture-expressed TSSs. However, none of these putative mammalian-specific *Bbives* have activity specific to mammalian infection by luciferase transcriptional fusion. *Bbive36*, *158* and *252* showed low levels of luciferase activity in culture despite having no associated TSSs by 5'RNA-seq. This could reflect the possible low stability of the transcripts in culture leading to their absence from the 5'RNA-seq libraries and/or differences in sensitivity among the techniques. This does not, however, rule out the possibility that of the 114 *Bbives* in this category, some are primarily active during mammalian infection. Indeed *Bbive161* and *175* had no detectable promoter activity in culture and no TSS detected by 5'RNA-seq. However, these sequences were suffi-

ciently active during murine infection to drive expression of *pncA* through BbIVET. Likely, we did not observe luciferase activity for these sequences by IVIS due to the sensitivity of the currently available IVIS machine. Indeed, even with our strongest promoter (*flaBp*) we only detect robust luciferase activity at days 7 and 10 post infection by IVIS. Furthermore, unlike what has recently been shown for detection of *ospCp* activity by IVIS (93), using our experimental system we did not detect *ospCp* activity above background until 7 days post infection. Importantly, transcript levels do not necessarily correlate to biological relevance. Indeed, our group has recently demonstrated by quantitative RT-PCR analysis of *B. burgdorferi* infected mouse tissues at 10 days post infection that the transcript level of the BbIVET-identified and infection-essential gene *bb0318* is ~40-fold lower than that of the *ospC* transcript ((55) and unpublished data, P.P.A. and M.W.J.). Together, our findings indicate the sensitivity of BbIVET to identify low activity promoters and the potential for discovering *B. burgdorferi* infection-essential transcripts through BbIVET. These data demonstrate, for the first time, the expression of various types of previously un-annotated RNAs during *B. burgdorferi* infection of mice, including antisense and internal transcripts. Together our findings provide a framework for future studies focused on defining the contributions of these novel transcripts to the molecular mechanisms of *B. burgdorferi* pathogenesis.

CONCLUSIONS

The data sets described herein provide a significant resource for the spirochete community and others interested in bacterial transcriptomes. The 5'RNA-seq data have been uploaded to an interactive browser, available for viewing at www.ucf.edu/research/interactive-genomics/lyme-disease. This work provides the first examples of *B. burgdorferi* expression of non-annotated RNAs during mammalian infection and lays the foundation for mechanistic studies focused on elucidation of the contributions of RNA-based regulation to *B. burgdorferi* pathogenesis. With the continued advancement of high throughput sequencing methods and publication of ever increasing numbers of 5' end deep sequencing data sets, the bottleneck in research innovation becomes validation and prioritization of novel transcripts of interest. This is particularly important for bacterial pathogens and understanding the biological significance of genetically intractable transcripts such as antisense and internal RNAs. We have used a unique synergistic approach of combining 5'RNA-seq and IVET, along with luciferase promoter fusions, to validate the expression of primary, antisense and internal transcripts during an active infection. This work encompasses the first application of 5'RNA-seq to validate a global promoter-activity based screen. The infection-model discovery and validation approach that we present is broadly applicable to any pathogen of interest providing (i) strand specific validation of novel transcripts expressed during infection, (ii) identification of transcripts of interest for mechanistic studies and (iii) transcriptional analysis in pathogens that do not achieve high loads during infection. In sum, this work contributes significant insight into the transcriptome

of *B. burgdorferi* and provides an innovative approach for analysis of 5' end RNA-seq data from medically relevant pathogens.

AVAILABILITY

The complete BbIVET sequences, including *Bbive* boundaries and those that are associated to TSSs are provided in Supplementary Table S2. The 5'RNA-seq data have been deposited to SRA at NCBI (Accession numbers: SRR4423918, SRR4423919, SRR4423920, SRR4423921). A complete list of 5' ends identified in this study with genomic location and predicted annotation is provided in Supplementary Tables S3, S4 and S5. An interactive genome browser containing the 5'RNA-seq data described herein can be found at www.ucf.edu/research/interactive-genomics/lyme-disease.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

The authors would like to Dr Jon Blevins and Dr Michael Norgard for generously providing the pJSB161 and pJSB175 plasmids, Dr Nikhat Praveen for technical suggestions related to IVIS and Dr Kyle Rohde for use of his plate reader. The authors would like to thank Dr Travis Jewett and members of the M. Jewett lab for insightful discussions and critical analysis. The authors would like to thank Philipp Rescheneder and Alex Lazin for assistance with bioinformatics, the UCF L.E.A.R.N. students, Carlos Tapia and Brianna King, for technical support. The authors would like to thank the UCF NAF animal care staff, Craig Anderson and the UCF COM HIT team. The authors wish to acknowledge the Vienna BioCenter Core Facilities (VBCF) for providing initial assistance in RNA-seq, and John Marchica and Subramaniam Shyamalagovindarajan at Sanford Burnham Prebys Medical Discovery Institute for performing the Illumina sequencing.

Author contributions: I.B., M.L. and R.S. developed the 5' end RNA-seq method. P.P.A. generated the *B. burgdorferi* 5'RNA-seq libraries. P.P.A., M.L., R.S. and M.W.J. designed experiments. P.P.A. and C.F.A. performed experiments. N.P. and P.P.A. performed bioinformatics analyses. P.P.A., C.F.A., N.P., M.L., I.B. and M.W.J. interpreted experimental results. P.P.A. and M.W.J. wrote the manuscript. All authors critiqued and edited the final manuscript.

FUNDING

National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI099094 to M.W.J.]; National Research Fund for Tick-Borne Diseases [to M.W.J.]; University of Central Florida College of Medicine [to M.W.J.]; Austrian Science Fund [FWF F4301 and F4308 to R.S.]; University of Vienna [to R.S.]. Funding for open access charge; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI099094 to M.W.J.].

Conflict of interest statement. None declared.

REFERENCES

- Adeolu, M. and Gupta, R.S. (2014) A phylogenomic and molecular marker based proposal for the division of the genus *Borrelia* into two genera: the emended genus *Borrelia* containing only the members of the relapsing fever *Borrelia*, and the genus *Borreliella* gen. nov. containing the members of the Lyme disease *Borrelia* (*Borrelia burgdorferi* sensu lato complex). *Antonie Van Leeuwenhoek*, **105**, 1049–1072.
- Schotthoefer, A.M. and Frost, H.M. (2015) Ecology and Epidemiology of Lyme Borreliosis. *Clin. Lab. Med.*, **35**, 723–743.
- Radolf, J.D., Caimano, M.J., Stevenson, B. and Hu, L.T. (2012) Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. *Nat. Rev. Microbiol.*, **10**, 87–99.
- Tilly, K., Rosa, P.A. and Stewart, P.E. (2008) Biology of infection with *Borrelia burgdorferi*. *Infect. Dis. Clin. North Am.*, **22**, 217–234.
- Groshong, A.M. and Blevins, J.S. (2014) Insights into the biology of *Borrelia burgdorferi* gained through the application of molecular genetics. *Adv. Appl. Microbiol.*, **86**, 41–143.
- Samuels, D.S. (2011) Gene regulation in *Borrelia burgdorferi*. *Annu. Rev. Microbiol.*, **65**, 479–499.
- Iyer, R., Caimano, M.J., Luthra, A., Axline, D. Jr, Corona, A., Iacobas, D.A., Radolf, J.D. and Schwartz, I. (2015) Stage-specific global alterations in the transcriptomes of Lyme disease spirochetes during tick feeding and following mammalian host adaptation. *Mol. Microbiol.*, **95**, 509–538.
- Schwan, T.G. (2003) Temporal regulation of outer surface proteins of the Lyme-disease spirochaete *Borrelia burgdorferi*. *Biochem. Soc. Trans.*, **31**, 108–112.
- Schwan, T.G. and Piesman, J. (2000) Temporal changes in outer surface proteins A and C of the Lyme disease-associated spirochete, *Borreliaburgdorferi*, during the chain of infection in ticks and mice. *J. Clin. Microbiol.*, **38**, 382–388.
- Srivastava, S.Y. and de Silva, A.M. (2008) Reciprocal expression of *ospA* and *ospC* in single cells of *Borrelia burgdorferi*. *J. Bacteriol.*, **190**, 3429–3433.
- Montgomery, R.R., Malawista, S.E., Feen, K.J. and Bockenstedt, L.K. (1996) Direct demonstration of antigenic substitution of *Borrelia burgdorferi* *ex vivo*: exploration of the paradox of the early immune response to outer surface proteins A and C in Lyme disease. *J. Exp. Med.*, **183**, 261–269.
- Schwan, T.G., Piesman, J., Golde, W.T., Dolan, M.C. and Rosa, P.A. (1995) Induction of an outer surface protein on *Borrelia burgdorferi* during tick feeding. *Proc. Natl. Acad. Sci. U.S.A.*, **92**, 2909–2913.
- Westermann, A.J., Forstner, K.U., Amman, F., Barquist, L., Chao, Y., Schulte, L.N., Muller, L., Reinhardt, R., Stadler, P.F. and Vogel, J. (2016) Dual RNA-seq unveils noncoding RNA functions in host-pathogen interactions. *Nature*, **529**, 496–501.
- Fiedler, T., Sugareva, V., Patenge, N. and Kreikemeyer, B. (2010) Insights into *Streptococcus pyogenes* pathogenesis from transcriptome studies. *Future Microbiol.*, **5**, 1675–1694.
- Hsiao, A. and Zhu, J. (2009) Genetic tools to study gene expression during bacterial pathogen infection. *Adv. Appl. Microbiol.*, **67**, 297–314.
- La, M.V., Raoult, D. and Renesto, P. (2008) Regulation of whole bacterial pathogen transcription within infected hosts. *FEMS Microbiol. Rev.*, **32**, 440–460.
- Sturdevant, D.E., Virtaneva, K., Martens, C., Bozinov, D., Ogundare, O., Castro, N., Kanakabandi, K., Beare, P.A., Omsland, A., Carlson, J.H. *et al.* (2010) Host-microbe interaction systems biology: lifecycle transcriptomics and comparative genomics. *Future Microbiol.*, **5**, 205–219.
- Liang, F.T., Nelson, F.K. and Fikrig, E. (2002) Molecular adaptation of *Borrelia burgdorferi* in the murine host. *J. Exp. Med.*, **196**, 275–280.
- Ojaimi, C., Brooks, C., Casjens, S., Rosa, P., Elias, A., Barbour, A., Jasinskas, A., Benach, J., Katona, L., Radolf, J. *et al.* (2003) Profiling of temperature-induced changes in *Borrelia burgdorferi* gene expression by using whole genome arrays. *Infect. Immun.*, **71**, 1689–1705.
- Revel, A.T., Talaat, A.M. and Norgard, M.V. (2002) DNA microarray analysis of differential gene expression in *Borrelia burgdorferi*, the

- Lyme disease spirochete. *Proc. Natl. Acad. Sci. U.S.A.*, **99**, 1562–1567.
21. Livengood, J.A., Schmit, V.L. and Gilmore, R.D. Jr (2008) Global transcriptome analysis of *Borrelia burgdorferi* during association with human neuroglial cells. *Infect. Immun.*, **76**, 298–307.
 22. Tokarz, R., Anderton, J.M., Katona, L.I. and Benach, J.L. (2004) Combined effects of blood and temperature shift on *Borrelia burgdorferi* gene expression as determined by whole genome DNA array. *Infect. Immun.*, **72**, 5419–5432.
 23. Brooks, C.S., Hefty, P.S., Jolliff, S.E. and Akins, D.R. (2003) Global analysis of *Borrelia burgdorferi* genes regulated by mammalian host-specific signals. *Infect. Immun.*, **71**, 3371–3383.
 24. Caimano, M.J., Iyer, R., Eggers, C.H., Gonzalez, C., Morton, E.A., Gilbert, M.A., Schwartz, I. and Radolf, J.D. (2007) Analysis of the RpoS regulon in *Borrelia burgdorferi* in response to mammalian host signals provides insight into RpoS function during the enzootic cycle. *Mol. Microbiol.*, **65**, 1193–1217.
 25. Narasimhan, S., Caimano, M.J., Liang, F.T., Santiago, F., Laskowski, M., Philipp, M.T., Pachner, A.R., Radolf, J.D. and Fikrig, E. (2003) *Borrelia burgdorferi* transcriptome in the central nervous system of non-human primates. *Proc. Natl. Acad. Sci. U.S.A.*, **100**, 15953–15958.
 26. Yang, X., Coleman, A.S., Anguita, J. and Pal, U. (2009) A chromosomally encoded virulence factor protects the Lyme disease pathogen against host-adaptive immunity. *Plos Pathog.*, **5**, e1000326.
 27. Lin, T., Gao, L., Zhang, C., Odeh, E., Jacobs, M.B., Coutte, L., Chaconas, G., Philipp, M.T. and Norris, S.J. (2012) Analysis of an Ordered, Comprehensive STM Mutant Library in Infectious *Borrelia burgdorferi*: Insights into the Genes Required for Mouse Infectivity. *PloS One*, **7**, e47532.
 28. Troy, E.B., Lin, T., Gao, L., Lazinski, D.W., Lundt, M., Camilli, A., Norris, S.J. and Hu, L.T. (2016) Global Tn-seq analysis of carbohydrate utilization and vertebrate infectivity of *Borrelia burgdorferi*. *Mol. Microbiol.*, **101**, 1003–1023.
 29. Ellis, T.C., Jain, S., Linowski, A.K., Rike, K., Bestor, A., Rosa, P.A., Halpern, M., Kurhanewicz, S. and Jewett, M.W. (2014) *In vivo* expression technology identifies a novel virulence factor critical for *Borrelia burgdorferi* persistence in mice. *Plos Pathog.*, **10**, e1004260.
 30. Hanin, A., Sava, I., Bao, Y., Huebner, J., Hartke, A., Auffray, Y. and Sauvageot, N. (2010) Screening of *in vivo* activated genes in *Enterococcus faecalis* during insect and mouse infections and growth in urine. *PloS One*, **5**, e11879.
 31. Jackson, R.W. and Giddens, S.R. (2006) Development and application of *in vivo* expression technology (IVET) for analysing microbial gene expression in complex environments. *Infect. Disord. Drug Targets*, **6**, 207–240.
 32. Lee, S.W. and Cooksey, D.A. (2000) Genes expressed in *Pseudomonas putida* during colonization of a plant-pathogenic fungus. *Appl. Environ. Microbiol.*, **66**, 2764–2772.
 33. Mendez, J., Reimundo, P., Perez-Pascual, D., Navais, R., Gomez, E. and Guijarro, J.A. (2011) A novel *cdsAB* operon is involved in the uptake of L-cysteine and participates in the pathogenesis of *Yersinia ruckeri*. *J. Bacteriol.*, **193**, 944–951.
 34. Schlauch, J.M. and Camilli, A. (2000) IVET and RIVET: use of gene fusions to identify bacterial virulence factors specifically induced in host tissues. *Methods Enzymol.*, **326**, 73–96.
 35. Sharma, C.M., Hoffmann, S., Darfeuille, F., Reignier, J., Findeiss, S., Sittka, A., Chabas, S., Reiche, K., Hackermuller, J., Reinhardt, R. et al. (2010) The primary transcriptome of the major human pathogen *Helicobacter pylori*. *Nature*, **464**, 250–255.
 36. Cortes, T., Schubert, O.T., Rose, G., Arnvig, K.B., Comas, I., Aebersold, R. and Young, D.B. (2013) Genome-wide mapping of transcriptional start sites defines an extensive leaderless transcriptome in *Mycobacterium tuberculosis*. *Cell Rep.*, **5**, 1121–1131.
 37. Nuss, A.M., Heroven, A.K., Waldmann, B., Reinkensmeier, J., Jarek, M., Beckstette, M. and Dersch, P. (2015) Transcriptomic profiling of *Yersinia pseudotuberculosis* reveals reprogramming of the Crp regulon by temperature and uncovers Crp as a master regulator of small RNAs. *PLoS Genet.*, **11**, e1005087.
 38. Rosinski-Chupin, I., Sauvage, E., Sismeiro, O., Villain, A., Da Cunha, V., Caliot, M.E., Dillies, M.A., Trieu-Cuot, P., Boulloc, P., Lartigue, M.F. et al. (2015) Single nucleotide resolution RNA-seq uncovers new regulatory mechanisms in the opportunistic pathogen *Streptococcus agalactiae*. *BMC Genomics*, **16**, 419.
 39. Papenfort, K., Forstner, K.U., Cong, J.P., Sharma, C.M. and Bassler, B.L. (2015) Differential RNA-seq of *Vibrio cholerae* identifies the VqmR small RNA as a regulator of biofilm formation. *Proc. Natl. Acad. Sci. U.S.A.*, **112**, E766–E775.
 40. Dugar, G., Herbig, A., Forstner, K.U., Heidrich, N., Reinhardt, R., Nieselt, K. and Sharma, C.M. (2013) High-resolution transcriptome maps reveal strain-specific regulatory features of multiple *Campylobacter jejuni* isolates. *PLoS Genet.*, **9**, e1003495.
 41. Shell, S.S., Wang, J., Lapierre, P., Mir, M., Chase, M.R., Pyle, M.M., Gawande, R., Ahmad, R., Sarracino, D.A., Ioerger, T.R. et al. (2015) Leaderless transcripts and small proteins are common features of the mycobacterial translational landscape. *PLoS Genet.*, **11**, e1005641.
 42. Thomason, M.K., Bischler, T., Eisenbart, S.K., Forstner, K.U., Zhang, A., Herbig, A., Nieselt, K., Sharma, C.M. and Storz, G. (2015) Global transcriptional start site mapping using differential RNA sequencing reveals novel antisense RNAs in *Escherichia coli*. *J. Bacteriol.*, **197**, 18–28.
 43. Elias, A.F., Stewart, P.E., Grimm, D., Caimano, M.J., Eggers, C.H., Tilly, K., Bono, J.L., Akins, D.R., Radolf, J.D., Schwan, T.G. et al. (2002) Clonal polymorphism of *Borrelia burgdorferi* strain B31 MI: implications for mutagenesis in an infectious strain background. *Infect. Immun.*, **70**, 2139–2150.
 44. Rego, R.O., Bestor, A. and Rosa, P.A. (2011) Defining the plasmid-borne restriction-modification systems of the Lyme disease spirochete *Borrelia burgdorferi*. *J. Bacteriol.*, **193**, 1161–1171.
 45. Samuels, D.S. (1995) Methods in Molecular Biology. In: Nickoloff, J.A. (ed). *Electroporation Protocols for Microorganisms*. Humana Press, Inc., Totowa, N.J., Vol. **47**, pp. 253–259.
 46. Barbour, A.G. (1984) Isolation and cultivation of Lyme disease spirochetes. *Yale J. Biol. Med.*, **57**, 521–525.
 47. Rosa, P.A. and Hogan, D. (1992) In: Munderloh, U.G. and Kurtti, T.J. (eds). *Proceeding of the First International Conference on Tick Borne Pathogens at the Host-Vector Interface*. University of Minnesota, St. Paul, Minnesota, pp. 95–103.
 48. Drecktrah, D., Lybecker, M., Popitsch, N., Rescheneder, P., Hall, L.S. and Samuels, D.S. (2015) The *Borrelia burgdorferi* RelA/SpoT homolog and stringent response regulate survival in the tick vector and global gene expression during starvation. *Plos Pathog.*, **11**, e1005160.
 49. Sedlazeck, F.J., Rescheneder, P. and von Haeseler, A. (2013) NextGenMap: fast and accurate read mapping in highly polymorphic genomes. *Bioinformatics*, **29**, 2790–2791.
 50. Casjens, S., Palmer, N., van Vugt, R., Huang, W.M., Stevenson, B., Rosa, P., Lathigra, R., Sutton, G., Peterson, J., Dodson, R.J. et al. (2000) A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete *Borrelia burgdorferi*. *Mol. Microbiol.*, **35**, 490–516.
 51. Di, L., Pagan, P.E., Packer, D., Martin, C.L., Akther, S., Ramrattan, G., Mongodin, E.F., Fraser, C.M., Schutzer, S.E., Luft, B.J. et al. (2014) BorreliaBase: a phylogeny-centered browser of *Borrelia* genomes. *BMC Bioinformatics*, **15**, 233.
 52. Streit, S., Michalski, C.W., Erkan, M., Kleeff, J. and Friess, H. (2009) Northern blot analysis for detection and quantification of RNA in pancreatic cancer cells and tissues. *Nat. Protoc.*, **4**, 37–43.
 53. Blevins, J.S., Revel, A.T., Smith, A.H., Bachlani, G.N. and Norgard, M.V. (2007) Adaptation of a luciferase gene reporter and lac expression system to *Borrelia burgdorferi*. *Appl. Environ. Microbiol.*, **73**, 1501–1513.
 54. Jewett, M.W., Lawrence, K., Bestor, A.C., Tilly, K., Grimm, D., Shaw, P., VanRaden, M., Gherardini, F. and Rosa, P.A. (2007) The critical role of the linear plasmid lp36 in the infectious cycle of *Borrelia burgdorferi*. *Mol. Microbiol.*, **64**, 1358–1374.
 55. Showman, A.C., Aranjuez, G., Adams, P.P. and Jewett, M.W. (2016) Gene *bb0318* is critical for the oxidative stress response and infectivity of *Borrelia burgdorferi*. *Infect. Immun.*, **84**, 3141–3151.
 56. Shepherd, J. and Ibba, M. (2015) Bacterial transfer RNAs. *FEMS Microbiol. Rev.*, **39**, 280–300.
 57. Kroger, C., Dillon, S.C., Cameron, A.D., Papenfort, K., Sivasankaran, S.K., Hokamp, K., Chao, Y., Sittka, A., Hebrard, M., Handler, K. et al. (2012) The transcriptional landscape and small RNAs of *Salmonella enterica* serovar Typhimurium. *Proc. Natl. Acad. Sci. U.S.A.*, **109**, E1277–E1286.

58. Mendoza-Vargas, A., Olvera, L., Olvera, M., Grande, R., Vega-Alvarado, L., Taboada, B., Jimenez-Jacinto, V., Salgado, H., Juarez, K., Contreras-Moreira, B. *et al.* (2009) Genome-wide identification of transcription start sites, promoters and transcription factor binding sites in *E. coli*. *PLoS One*, **4**, e7526.
59. Bailey, T.L. and Elkan, C. (1994) Fitting a mixture model by expectation maximization to discover motifs in biopolymers. *Proc. Int. Conf. Intell. Syst. Mol. Biol.*, **2**, 28–36.
60. Kortmann, J. and Narberhaus, F. (2012) Bacterial RNA thermometers: molecular zippers and switches. *Nat. Rev. Microbiol.*, **10**, 255–265.
61. Tucker, B.J. and Breaker, R.R. (2005) Riboswitches as versatile gene control elements. *Curr. Opin. Struct. Biol.*, **15**, 342–348.
62. Dar, D., Shamir, M., Mellin, J.R., Koutero, M., Stern-Ginossar, N., Cossart, P. and Sorek, R. (2016) Term-seq reveals abundant ribo-regulation of antibiotics resistance in bacteria. *Science*, **352**, aad9822.
63. Irnov, I., Sharma, C.M., Vogel, J. and Winkler, W.C. (2010) Identification of regulatory RNAs in *Bacillus subtilis*. *Nucleic Acids Res.*, **38**, 6637–6651.
64. Wurtzel, O., Sesto, N., Mellin, J.R., Karunker, I., Edelheit, S., Becavin, C., Archambaud, C., Cossart, P. and Sorek, R. (2012) Comparative transcriptomics of pathogenic and non-pathogenic *Listeria* species. *Mol. Syst. Biol.*, **8**, 583.
65. Stazic, D. and Voss, B. (2015) The complexity of bacterial transcriptomes. *J. Biotechnol.*, **232**, 69–78.
66. Mandlik, A., Livny, J., Robins, W.P., Ritchie, J.M., Mekalanos, J.J. and Waldor, M.K. (2011) RNA-Seq-based monitoring of infection-linked changes in *Vibrio cholerae* gene expression. *Cell Host Microbe*, **10**, 165–174.
67. Muller, C., Cacaci, M., Sauvageot, N., Sanguinetti, M., Rattei, T., Eder, T., Giard, J.C., Kalinowski, J., Hain, T. and Hartke, A. (2015) The intraperitoneal transcriptome of the opportunistic pathogen *Enterococcus faecalis* in mice. *PLoS One*, **10**, e0126143.
68. Yan, Y., Su, S., Meng, X., Ji, X., Qu, Y., Liu, Z., Wang, X., Cui, Y., Deng, Z., Zhou, D. *et al.* (2013) Determination of sRNA expressions by RNA-seq in *Yersinia pestis* grown in vitro and during infection. *PLoS One*, **8**, e74495.
69. Deka, R.K., Brautigam, C.A., Bidy, B.A., Liu, W.Z. and Norgard, M.V. (2013) Evidence for an ABC-type riboflavin transporter system in pathogenic spirochetes. *mBio*, **4**, doi:10.1128/mBio.00615-12.
70. Arnold, W.K., Savage, C.R., Brissette, C.A., Seshu, J., Livny, J. and Stevenson, B. (2016) RNA-Seq of *Borrelia burgdorferi* in multiple phases of growth reveals insights into the dynamics of gene expression, transcriptome architecture and noncoding RNAs. *PLoS One*, **11**, e0164165.
71. Sultan, S.Z., Pitzer, J.E., Miller, M.R. and Motaleb, M.A. (2010) Analysis of a *Borrelia burgdorferi* phosphodiesterase demonstrates a role for cyclic-di-guanosine monophosphate in motility and virulence. *Mol. Microbiol.*, **77**, 128–142.
72. Brautigam, C.A., Ouyang, Z., Deka, R.K. and Norgard, M.V. (2014) Sequence, biophysical, and structural analyses of the PstS lipoprotein (BB0215) from *Borrelia burgdorferi* reveal a likely binding component of an ABC-type phosphate transporter. *Protein Sci.*, **23**, 200–212.
73. Kung, F., Kaur, S., Smith, A.A., Yang, X., Wilder, C.N., Sharma, K., Buyuktanir, O. and Pal, U. (2016) A *Borrelia burgdorferi* surface-exposed transmembrane protein lacking detectable immune responses supports pathogen persistence and constitutes a vaccine target. *J. Infect. Dis.*, **213**, 1786–1795.
74. Gaal, T., Bartlett, M.S., Ross, W., Turnbough, C.L. Jr and Gourse, R.L. (1997) Transcription regulation by initiating NTP concentration: rRNA synthesis in bacteria. *Science*, **278**, 2092–2097.
75. Jain, S., Sutchu, S., Rosa, P.A., Byram, R. and Jewett, M.W. (2012) *Borrelia burgdorferi* harbors a transport system essential for purine salvage and mammalian infection. *Infect. Immun.*, **80**, 3086–3093.
76. Jewett, M.W., Lawrence, K.A., Bestor, A., Byram, R., Gherardini, F. and Rosa, P.A. (2009) GuaA and GuaB are essential for *Borrelia burgdorferi* survival in the tick-mouse infection cycle. *J. Bacteriol.*, **191**, 6231–6241.
77. Lawrence, K.A., Jewett, M.W., Rosa, P.A. and Gherardini, F.C. (2009) *Borrelia burgdorferi* bb0426 encodes a 2'-deoxyribosyltransferase that plays a central role in purine salvage. *Mol. Microbiol.*, **72**, 1517–1529.
78. Jain, S., Showman, A.C. and Jewett, M.W. (2015) Molecular dissection of a *Borrelia burgdorferi* *in vivo* essential purine transport system. *Infect. Immun.*, **83**, 2224–2233.
79. Krasny, L., Tiserova, H., Jonak, J., Rejman, D. and Sanderova, H. (2008) The identity of the transcription +1 position is crucial for changes in gene expression in response to amino acid starvation in *Bacillus subtilis*. *Mol. Microbiol.*, **69**, 42–54.
80. Babski, J., Haas, K.A., Nather-Schindler, D., Pfeiffer, F., Forstner, K.U., Hammelmann, M., Hilker, R., Becker, A., Sharma, C.M., Marchfelder, A. *et al.* (2016) Genome-wide identification of transcriptional start sites in the haloarchaeon *Haloflex volcanii* based on differential RNA-Seq (dRNA-Seq). *BMC Genomics*, **17**, 629.
81. Lybecker, M., Bilusic, I. and Raghavan, R. (2014) Pervasive transcription: detecting functional RNAs in bacteria. *Transcription*, **5**, e944039.
82. Moll, I., Grill, S., Gualerzi, C.O. and Blasi, U. (2002) Leaderless mRNAs in bacteria: surprises in ribosomal recruitment and translational control. *Mol. Microbiol.*, **43**, 239–246.
83. Vesper, O., Amitai, S., Belitsky, M., Byrgazov, K., Kaberdina, A.C., Engelberg-Kulka, H. and Moll, I. (2011) Selective translation of leaderless mRNAs by specialized ribosomes generated by MazF in *Escherichia coli*. *Cell*, **147**, 147–157.
84. Smith, A.M., Fuchs, R.T., Grundy, F.J. and Henkin, T.M. (2010) Riboswitch RNAs: regulation of gene expression by direct monitoring of a physiological signal. *RNA Biol.*, **7**, 104–110.
85. Henkin, T.M. and Yanofsky, C. (2002) Regulation by transcription attenuation in bacteria: how RNA provides instructions for transcription termination/antitermination decisions. *Bioessays*, **24**, 700–707.
86. Lybecker, M.C. and Samuels, D.S. (2007) Temperature-induced regulation of RpoS by a small RNA in *Borrelia burgdorferi*. *Mol. Microbiol.*, **64**, 1075–1089.
87. Bian, J., Shen, H., Tu, Y., Yu, A. and Li, C. (2011) The riboswitch regulates a thiamine pyrophosphate ABC transporter of the oral spirochete *Treponema denticola*. *J. Bacteriol.*, **193**, 3912–3922.
88. Caimano, M.J., Dunham-Ems, S., Allard, A.M., Cassera, M.B., Kenedy, M. and Radolf, J.D. (2015) Cyclic di-GMP modulates gene expression in Lyme disease spirochetes at the tick-mammal interface to promote spirochete survival during the blood meal and tick-to-mammal transmission. *Infect. Immun.*, **83**, 3043–3060.
89. He, M., Ouyang, Z., Troxell, B., Xu, H., Moh, A., Piesman, J., Norgard, M.V., Gomelsky, M. and Yang, X.F. (2011) Cyclic di-GMP is essential for the survival of the Lyme disease spirochete in ticks. *PLoS Pathog.*, **7**, e1002133.
90. Fraser, C.M., Casjens, S., Huang, W.M., Sutton, G.G., Clayton, R., Lathigra, R., White, O., Ketchum, K.A., Dodson, R., Hickey, E.K. *et al.* (1997) Genomic sequence of a Lyme disease spirochaete, *Borrelia burgdorferi*. *Nature*, **390**, 580–586.
91. Pappas, C.J., Iyer, R., Petzke, M.M., Caimano, M.J., Radolf, J.D. and Schwartz, I. (2011) *Borrelia burgdorferi* requires glycerol for maximum fitness during the tick phase of the enzootic cycle. *PLoS Pathog.*, **7**, e1002102.
92. Sudarsan, N., Lee, E.R., Weinberg, Z., Moy, R.H., Kim, J.N., Link, K.H. and Breaker, R.R. (2008) Riboswitches in eubacteria sense the second messenger cyclic di-GMP. *Science*, **321**, 411–413.
93. Skare, J.T., Shaw, D.K., Trzeciakowski, J.P. and Hyde, J.A. (2016) *In vivo* imaging demonstrates that *Borrelia burgdorferi* *ospC* is uniquely expressed temporally and spatially throughout experimental infection. *PLoS one*, **11**, e0162501.
94. Jonsson, M., Noppa, L., Barbour, A.G. and Bergstrom, S. (1992) Heterogeneity of outer membrane proteins in *Borrelia burgdorferi*: comparison of *osp* operons of three isolates of different geographic origins. *Infect. Immun.*, **60**, 1845–1853.
95. Rhodes, R.G., Coy, W. and Nelson, D.R. (2009) Chitobiose utilization in *Borrelia burgdorferi* is dually regulated by RpoD and RpoS. *BMC Microbiol.*, **9**, 108.
96. von Lackum, K., Ollison, K.M., Bykowski, T., Nowalk, A.J., Hughes, J.L., Carroll, J.A., Zuckert, W.R. and Stevenson, B. (2007) Regulated synthesis of the *Borrelia burgdorferi* inner-membrane lipoprotein IpLA7 (P22, P22-A) during the Lyme disease

- spirochaete's mammal-tick infectious cycle. *Microbiology*, **153**, 1361–1371.
97. Motaleb, M.A., Sultan, S.Z., Miller, M.R., Li, C. and Charon, N.W. (2011) CheY3 of *Borrelia burgdorferi* is the key response regulator essential for chemotaxis and forms a long-lived phosphorylated intermediate. *J. Bacteriol.*, **193**, 3332–3341.
98. Jutras, B.L., Jones, G.S., Verma, A., Brown, N.A., Antonicello, A.D., Chenail, A.M. and Stevenson, B. (2013) Posttranscriptional self-regulation by the Lyme disease bacterium's BpuR DNA/RNA-binding protein. *J. Bacteriol.*, **195**, 4915–4923.
99. Zhang, H., Raji, A., Theisen, M., Hansen, P.R. and Marconi, R.T. (2005) bdrF2 of Lyme disease spirochetes is coexpressed with a series of cytoplasmic proteins and is produced specifically during early infection. *J. Bacteriol.*, **187**, 175–184.
100. Marconi, R.T., Samuels, D.S. and Garon, C.F. (1993) Transcriptional analyses and mapping of the *ospC* gene in Lyme disease spirochetes. *J. Bacteriol.*, **175**, 926–932.
101. Margolis, N., Hogan, D., Tilly, K. and Rosa, P.A. (1994) Plasmid location of *Borrelia* purine biosynthesis gene homologs. *J. Bacteriol.*, **176**, 6427–6432.
102. Padula, S.J., Sampieri, A., Dias, F., Szczepanski, A. and Ryan, R.W. (1993) Molecular characterization and expression of p23 (OspC) from a North American strain of *Borrelia burgdorferi*. *Infect. Immun.*, **61**, 5097–5105.